Novel target to kill CLL

Blood. 2015 Jan 8;125(2):211-2. doi: 10.1182/blood-2014-10-606582.

Abstract

In this issue of Blood, Liu et al report on OSU-T315, a new agent that specifically disrupts the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) pathway and shows high proapoptotic activity against chronic lymphocytic leukemia (CLL) cells, which may indicate a potential therapeutic application in this disease

Publication types

  • Comment

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology*
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell / metabolism*
  • Proto-Oncogene Proteins c-akt / antagonists & inhibitors*

Substances

  • Antineoplastic Agents
  • Proto-Oncogene Proteins c-akt